| Attribute |
Value |
| 52 Week Change |
0.20554924 |
| Address1 |
1 North Waukegan Road |
| All Time High |
267.47 |
| All Time Low |
33.33 |
| Ask |
255.88 |
| Ask Size |
200 |
| Audit Risk |
6 |
| Average Analyst Rating |
1.7 - Buy |
| Average Daily Volume10 Day |
4,442,690 |
| Average Daily Volume3 Month |
6,530,098 |
| Average Volume |
6,530,098 |
| Average Volume10Days |
4,442,690 |
| Beta |
0.28 |
| Bid |
255.9 |
| Bid Size |
200 |
| Board Risk |
5 |
| Book Value |
-3.359 |
| City |
North Chicago |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
2 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
255.48 |
| Current Ratio |
0.809 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,786,665,600 |
| Day High |
259.0 |
| Day Low |
255.0797 |
| Display Name |
AbbVie |
| Dividend Date |
1,786,665,600 |
| Dividend Rate |
6.92 |
| Dividend Yield |
2.71 |
| Earnings Call Timestamp End |
1,785,502,800 |
| Earnings Call Timestamp Start |
1,785,502,800 |
| Earnings Growth |
2.904 |
| Earnings Quarterly Growth |
2.852 |
| Earnings Timestamp |
1,785,501,000 |
| Earnings Timestamp End |
1,793,277,000 |
| Earnings Timestamp Start |
1,793,277,000 |
| Ebitda |
30,762,999,808 |
| Ebitda Margins |
0.47779 |
| Enterprise To Ebitda |
16.768 |
| Enterprise To Revenue |
8.011 |
| Enterprise Value |
515,826,122,752 |
| Eps Current Year |
14.0106 |
| Eps Forward |
16.28202 |
| Eps Trailing Twelve Months |
3.5 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,784,073,600 |
| Exchange |
NYQ |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
251.7682 |
| Fifty Day Average Change |
3.711792 |
| Fifty Day Average Change Percent |
0.014742894 |
| Fifty Two Week Change Percent |
20.554924 |
| Fifty Two Week High |
267.47 |
| Fifty Two Week High Change |
-11.9900055 |
| Fifty Two Week High Change Percent |
-0.044827476 |
| Fifty Two Week Low |
190.75 |
| Fifty Two Week Low Change |
64.729996 |
| Fifty Two Week Low Change Percent |
0.33934468 |
| Fifty Two Week Range |
190.75 - 267.47 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,357,137,000,000 |
| Five Year Avg Dividend Yield |
3.6 |
| Float Shares |
1,763,989,487 |
| Forward Eps |
16.28202 |
| Forward P E |
15.690927 |
| Free Cashflow |
16,870,250,496 |
| Full Exchange Name |
NYSE |
| Full Time Employees |
57,000 |
| Fullday Change |
-2.67 |
| Fullday Change Percent |
-1.03428 |
| Fullday Price |
255.5267 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,785,542,400 |
| Gross Margins |
0.72792 |
| Gross Profits |
46,868,000,768 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.0011 |
| Held Percent Institutions |
0.77436996 |
| Implied Shares Outstanding |
1,767,117,285 |
| Industry |
Drug Manufacturers - General |
| Industry Disp |
Drug Manufacturers - General |
| Industry Key |
drug-manufacturers-general |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Dividend Date |
1,784,073,600 |
| Last Dividend Value |
1.73 |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
| Long Name |
AbbVie Inc. |
| Market |
us_market |
| Market Cap |
451,463,118,848 |
| Market State |
CLOSED |
| Max Age |
86,400 |
| Message Board Id |
finmb_141885706 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
6,270,000,128 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
456,181,327,122 |
| Number Of Analyst Opinions |
29 |
| Open |
258.67 |
| Operating Cashflow |
19,506,999,296 |
| Operating Margins |
0.40035 |
| Overall Risk |
7 |
| Payout Ratio |
1.9039999 |
| Peg Ratio |
0.42 |
| Phone |
847 932 7900 |
| Post Market Change |
0.046707153 |
| Post Market Change Percent |
0.018282117 |
| Post Market Price |
255.5267 |
| Post Market Time |
1,787,961,588 |
| Previous Close |
258.15 |
| Price Eps Current Year |
18.234764 |
| Price Hint |
2 |
| Price To Book |
-76.05835 |
| Price To Sales Trailing12 Months |
7.0118213 |
| Profit Margins |
0.098000005 |
| Quick Ratio |
0.49 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
1.67742 |
| Region |
US |
| Regular Market Change |
-2.67 |
| Regular Market Change Percent |
-1.03428 |
| Regular Market Day High |
259.0 |
| Regular Market Day Low |
255.0797 |
| Regular Market Day Range |
255.0797 - 259.0 |
| Regular Market Open |
258.67 |
| Regular Market Previous Close |
258.15 |
| Regular Market Price |
255.48 |
| Regular Market Time |
1,787,947,355 |
| Regular Market Volume |
3,222,214 |
| Return On Assets |
0.105100006 |
| Revenue Growth |
0.102 |
| Revenue Per Share |
36.387 |
| Sand P52 Week Change |
0.20204377 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
9 |
| Shares Outstanding |
1,767,117,285 |
| Shares Percent Shares Out |
0.0104 |
| Shares Short |
18,299,894 |
| Shares Short Previous Month Date |
1,784,073,600 |
| Shares Short Prior Month |
22,632,412 |
| Short Name |
AbbVie Inc. |
| Short Percent Of Float |
0.0115 |
| Short Ratio |
3.36 |
| Source Interval |
15 |
| State |
IL |
| Symbol |
ABBV |
| Target High Price |
328.0 |
| Target Low Price |
200.0 |
| Target Mean Price |
276.5862 |
| Target Median Price |
280.0 |
| Total Cash |
6,568,999,936 |
| Total Cash Per Share |
3.717 |
| Total Debt |
70,884,999,168 |
| Total Revenue |
64,385,998,848 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
6.83 |
| Trailing Annual Dividend Yield |
0.026457487 |
| Trailing Eps |
3.5 |
| Trailing P E |
72.994286 |
| Trailing Peg Ratio |
0.4222 |
| Triggerable |
1 |
| Two Hundred Day Average |
227.6508 |
| Two Hundred Day Average Change |
27.829193 |
| Two Hundred Day Average Change Percent |
0.12224509 |
| Type Disp |
Equity |
| Volume |
3,222,214 |
| Website |
https://www.abbvie.com |
| Zip |
60,064-6400 |